A Phase III Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients.

Trial Profile

A Phase III Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Feb 2012

At a glance

  • Drugs Idebenone (Primary)
  • Indications Cardiomyopathies; Friedreich's ataxia
  • Focus Therapeutic Use
  • Acronyms IONIA
  • Sponsors Santhera Pharmaceuticals
  • Most Recent Events

    • 05 Apr 2011 Results presented at the 60th Annual Scientific Session of the American College of Cardiology.
    • 01 Mar 2011 Results for secondary cardiac endpoints published in the American Heart Journal.
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top